European Commission approves Rinvoq for moderate to severe UC
The European Commission approved Rinvoq for the treatment of patients with moderate to severe ulcerative colitis who had an inadequate response, lost response or were intolerant to conventional therapy, according to an AbbVie press release.Approval of Rinvoq (upadacitinib, AbbVie) was based on results from three phase 3 studies, in which the primary endpoint of clinical remission was achieved at week 8 in two induction studies (45 mg upadacitinib, U-ACHIEVE and U-ACCCOMPLISH) and at week 52 in the U-ACHIEVE maintenance study (15 mg and 30 mg). Rinvoq also induced secondary endpoints ofRead More